H.C. Wainwright assumed coverage of Bolt Biotherapeutics (BOLT) with a Buy rating and $7 price target The company’s lead asset, BDC-4182, differentiates itself relative to antibody-drug conjugates since the payload is an immune-stimulatory agent instead of a cytotoxic warhead, the analyst tells investors in a research note. The firm says initial clinical results for BDC-4182 are expected in Q3 of 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BOLT: